Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 9/20 | 0.96 |
| ▸ | HTR3A known ✓ | P46098 | 4/20 | 0.61 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 3/20 | 0.61 |
| ▸ | HTR3B known ✓ | O95264 | 3/20 | 0.61 |
| ▸ | HTR3D known ✓ | Q70Z44 | 3/20 | 0.61 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 3/20 | 0.61 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.61 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.55 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.54 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.51 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.51 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.51 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.51 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.51 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.55 |
| ▸ | ESRRB | O95718 | 2/20 | 0.54 |
| ▸ | ESRRG | P62508 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3719334 | 1.00 | ADRB1 (0.96) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL81940 | 0.98 | ADRB1 (1.00) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6645952 | 0.98 | ADRB1 (1.00) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| Water SCHEMBL27430691 | 0.94 | ADRB1 (0.92) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| Dimethylamine SCHEMBL28750709 | 0.92 | ADRB1 (0.88) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL82301 | 0.90 | ADRB1 (0.85) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| Bicarbonate SCHEMBL11620170 | 0.88 | ADRB1 (0.81) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7136974 | 0.87 | ADRB1 (0.79) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL21548392 | 0.87 | ADRB1 (0.79) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL2881718 | 0.87 | ADRB1 (0.79) | ADRB1HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2668165-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| CN-103328449-A | Novel tetrahydroquinoline derivatives | HOFFMANN LA ROCHE | 2013-09-25 | — | — | CN | disclosed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110046135-A1 | NEW COMPOUNDS I | ASTRAZENECA AB (PUBL) (SE) | 2011-02-24 | — | — | US | disclosed |
| US-7851471-B2 | Compounds I | ASTRAZENECA AB (PUBL) (SE) | 2010-12-14 | — | — | US | disclosed |
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | BARTA THOMAS E | 2006-04-20 | — | — | US | disclosed |
| US-6750233-B2 | SELECTIVITY | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| EP-1268454-A1 | SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074796-A1 | SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
| US-6221868-B1 | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0995741-A1 | REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-5922719-A | 4-AROMATIC-SUBSTITUTED-PIPERAZIN-1-YLMETHYLCHROMEN-2-ONES | WARNER-LAMBERT COMPANY (US) | 1999-07-13 | — | — | US | disclosed |
| US-5563144-A | SERATONIN ANTAGONISTS FOR TREATMENT OF DISORDERS OF CENTRAL NERVOUS, CARDIOVASCULAR AND GASTROINTESTINAL SYSTEMS | RHONE-POULENC RORER S.A. (FR) | 1996-10-08 | — | — | US | disclosed |
| US-5086055-A | Treating asthma, rhinitis, atopic dermatitis, chronic hives and conjunctivitis | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-02-04 | — | — | US | disclosed |
| US-4140775-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | RAB1A, RABL3, RAB7A | ADRB1 377/4885HTR3A 598/4885HTR3E 731/4885 |
| US-20110046135-A1 | NEW COMPOUNDS I | GPR119, GLP1R, FABP4 | ADRB1 144/4885HTR3A 1570/4885HTR3E 1462/4885 |
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP13, MMP9, MMP3 | ADRB1 4210/4885HTR3A 479/4885HTR3E 340/4885 |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | GPR119, FABP4, ADIPOR2 | ADRB1 240/4885HTR3A 1392/4885HTR3E 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.